BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Seattle - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Seattle
X-ORIGINAL-URL:https://scienceinseattle.com
X-WR-CALDESC:Events for Science in Seattle
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20190310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20191103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200420T090000
DTEND;TZID=America/Vancouver:20200420T100000
DTSTAMP:20260403T192617
CREATED:20200330T211405Z
LAST-MODIFIED:20200330T211405Z
UID:25547-1587373200-1587376800@scienceinseattle.com
SUMMARY:Webinar: Hematopoietic Cell Therapy Products - Determining Potency and Stability
DESCRIPTION:There are unique challenges when it comes to cell therapy products\, including ensuring the reproducibility and consistency of product lots. These specific concerns arise from the inherent variability of the starting material\, which often comes from multiple patients or donors. Before using these cells as therapy\, the quality–including both purity and potency–of the final product must be established. This in turn requires reliable cell assays.\n\nThe best type of assay to measure the functionality of hematopoietic stem and progenitor cells (HSPCs) is an in vivo mouse model engraftment study; however\, these types of assays are time-consuming\, expensive\, and difficult to evaluate. Therefore\, the in vitro colony-forming unit (CFU) assay\, which has been shown to correlate well with in vivo engraftment models\, is recommended to evaluate the quality of HSPCs used in cell therapy. Several cord blood bank accrediting bodies (including AABB and FACT) now require pre-freeze CFU data from cord blood collection\, as evidence of sample stability and to ensure there is minimal loss of HSPCs during processing and cryopreservation.\n\nIn this webinar\, Dr. Jackie Damen of STEMCELL Technologies will explore the need for standardized potency assays for hematopoietic cell products and review recent publications that evaluate the effects of cryopreservation protocols on the potency of cell therapy products. Dr. Damen will define the CFU assay and explore its utility as part of the cell therapy workflow. She will also define simple steps that can help ensure standardization of the CFU assay\, including the use of automated imaging and analysis of cultures.\n\nLearning Objectives:\n\nDefine the CFU assay and its characteristics as a biological tool in identifying hematopoietic stem and progenitor cells\nIdentify publications using the CFU assay to verify the potency and stability of Hematopoietic Cellular Therapy Products\nUnderstand the utility of the CFU assay in the processing and manufacturing of Hematopoietic Cellular Therapy Products\n\n\n\nWebinars will be available for unlimited on-demand viewing after live event.\n\nLabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar\, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
URL:https://scienceinseattle.com/event/webinar-hematopoietic-cell-therapy-products-determining-potency-and-stability-2/
LOCATION:Online
ORGANIZER;CN="STEMCELL Technologies":MAILTO:info@stemcell.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200420T090000
DTEND;TZID=America/Vancouver:20200420T100000
DTSTAMP:20260403T192617
CREATED:20200330T211405Z
LAST-MODIFIED:20200330T211405Z
UID:26512-1587373200-1587376800@scienceinseattle.com
SUMMARY:Webinar: Hematopoietic Cell Therapy Products - Determining Potency and Stability
DESCRIPTION:There are unique challenges when it comes to cell therapy products\, including ensuring the reproducibility and consistency of product lots. These specific concerns arise from the inherent variability of the starting material\, which often comes from multiple patients or donors. Before using these cells as therapy\, the quality–including both purity and potency–of the final product must be established. This in turn requires reliable cell assays.\n\nThe best type of assay to measure the functionality of hematopoietic stem and progenitor cells (HSPCs) is an in vivo mouse model engraftment study; however\, these types of assays are time-consuming\, expensive\, and difficult to evaluate. Therefore\, the in vitro colony-forming unit (CFU) assay\, which has been shown to correlate well with in vivo engraftment models\, is recommended to evaluate the quality of HSPCs used in cell therapy. Several cord blood bank accrediting bodies (including AABB and FACT) now require pre-freeze CFU data from cord blood collection\, as evidence of sample stability and to ensure there is minimal loss of HSPCs during processing and cryopreservation.\n\nIn this webinar\, Dr. Jackie Damen of STEMCELL Technologies will explore the need for standardized potency assays for hematopoietic cell products and review recent publications that evaluate the effects of cryopreservation protocols on the potency of cell therapy products. Dr. Damen will define the CFU assay and explore its utility as part of the cell therapy workflow. She will also define simple steps that can help ensure standardization of the CFU assay\, including the use of automated imaging and analysis of cultures.\n\nLearning Objectives:\n\nDefine the CFU assay and its characteristics as a biological tool in identifying hematopoietic stem and progenitor cells\nIdentify publications using the CFU assay to verify the potency and stability of Hematopoietic Cellular Therapy Products\nUnderstand the utility of the CFU assay in the processing and manufacturing of Hematopoietic Cellular Therapy Products\n\n\n\nWebinars will be available for unlimited on-demand viewing after live event.\n\nLabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar\, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
URL:https://scienceinseattle.com/event/webinar-hematopoietic-cell-therapy-products-determining-potency-and-stability-3/
LOCATION:Online
ORGANIZER;CN="STEMCELL Technologies":MAILTO:info@stemcell.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200420T120000
DTEND;TZID=America/Vancouver:20200420T130000
DTSTAMP:20260403T192617
CREATED:20200417T210237Z
LAST-MODIFIED:20200417T210237Z
UID:8934-1587384000-1587387600@scienceinseattle.com
SUMMARY:Responding to COVID-19: Opportunities for All Researchers to Engage
DESCRIPTION:Right now\, all eyes are on an urgent science issue and its effects on our society. While everyone has a role to play in reducing the spread of the virus\, scientists have unique opportunities to respond to the crisis in impactful ways. For example\, some scientists might volunteer their lab or data analysis skills. Regardless of discipline\, researchers may find opportunities to pivot their research agenda to address timely and relevant questions. And others might serve as voices for science to amplify evidence\, reduce the spread of misinformation\, and advocate for science-informed approaches to managing the pandemic. This online panel discussion will include researchers from different disciplines who will share ideas for scientists looking to respond in the current moment.
URL:https://scienceinseattle.com/event/responding-to-covid-19-opportunities-for-all-researchers-to-engage/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200420T120000
DTEND;TZID=America/Vancouver:20200420T130000
DTSTAMP:20260403T192617
CREATED:20200417T210237Z
LAST-MODIFIED:20200417T210237Z
UID:25563-1587384000-1587387600@scienceinseattle.com
SUMMARY:Responding to COVID-19: Opportunities for All Researchers to Engage
DESCRIPTION:Right now\, all eyes are on an urgent science issue and its effects on our society. While everyone has a role to play in reducing the spread of the virus\, scientists have unique opportunities to respond to the crisis in impactful ways. For example\, some scientists might volunteer their lab or data analysis skills. Regardless of discipline\, researchers may find opportunities to pivot their research agenda to address timely and relevant questions. And others might serve as voices for science to amplify evidence\, reduce the spread of misinformation\, and advocate for science-informed approaches to managing the pandemic. This online panel discussion will include researchers from different disciplines who will share ideas for scientists looking to respond in the current moment.
URL:https://scienceinseattle.com/event/responding-to-covid-19-opportunities-for-all-researchers-to-engage-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200420T120000
DTEND;TZID=America/Vancouver:20200420T130000
DTSTAMP:20260403T192617
CREATED:20200417T210237Z
LAST-MODIFIED:20200417T210237Z
UID:26528-1587384000-1587387600@scienceinseattle.com
SUMMARY:Responding to COVID-19: Opportunities for All Researchers to Engage
DESCRIPTION:Right now\, all eyes are on an urgent science issue and its effects on our society. While everyone has a role to play in reducing the spread of the virus\, scientists have unique opportunities to respond to the crisis in impactful ways. For example\, some scientists might volunteer their lab or data analysis skills. Regardless of discipline\, researchers may find opportunities to pivot their research agenda to address timely and relevant questions. And others might serve as voices for science to amplify evidence\, reduce the spread of misinformation\, and advocate for science-informed approaches to managing the pandemic. This online panel discussion will include researchers from different disciplines who will share ideas for scientists looking to respond in the current moment.
URL:https://scienceinseattle.com/event/responding-to-covid-19-opportunities-for-all-researchers-to-engage-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T100000
DTEND;TZID=America/Vancouver:20200421T110000
DTSTAMP:20260403T192617
CREATED:20200326T222814Z
LAST-MODIFIED:20200326T222814Z
UID:8687-1587463200-1587466800@scienceinseattle.com
SUMMARY:North American Vascular Biology Organization (NAVBO) Online Mini-Symposia
DESCRIPTION:An online mini-symposium featuring four presentations:\n\nRenal stromal netrin-1 signaling drives kidney arterial development (Xiaowu Gu\, UT Southwestern)\nInhibition of Notch signaling in pericytes leads to AVM-like lesions (Taliha Nadeem\, University of Illinois\, Chicago)\nDach1 Promotes Coronary Artery Endothelial Cell Specification (Brian Raftrey\, Stanford University)\nPro-angiogenic properties of Purified Exosome Product (PEP) (Ao Shi\, Mayo Clinic) The session will be moderated by Kayla Bayless\, Texas A&M University
URL:https://scienceinseattle.com/event/north-american-vascular-biology-organization-navbo-online-mini-symposia/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/03/NAVBO.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T100000
DTEND;TZID=America/Vancouver:20200421T110000
DTSTAMP:20260403T192617
CREATED:20200326T222814Z
LAST-MODIFIED:20200326T222814Z
UID:25544-1587463200-1587466800@scienceinseattle.com
SUMMARY:North American Vascular Biology Organization (NAVBO) Online Mini-Symposia
DESCRIPTION:An online mini-symposium featuring four presentations:\n\nRenal stromal netrin-1 signaling drives kidney arterial development (Xiaowu Gu\, UT Southwestern)\nInhibition of Notch signaling in pericytes leads to AVM-like lesions (Taliha Nadeem\, University of Illinois\, Chicago)\nDach1 Promotes Coronary Artery Endothelial Cell Specification (Brian Raftrey\, Stanford University)\nPro-angiogenic properties of Purified Exosome Product (PEP) (Ao Shi\, Mayo Clinic) The session will be moderated by Kayla Bayless\, Texas A&M University
URL:https://scienceinseattle.com/event/north-american-vascular-biology-organization-navbo-online-mini-symposia-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/03/NAVBO.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T100000
DTEND;TZID=America/Vancouver:20200421T110000
DTSTAMP:20260403T192617
CREATED:20200326T222814Z
LAST-MODIFIED:20200326T222814Z
UID:26509-1587463200-1587466800@scienceinseattle.com
SUMMARY:North American Vascular Biology Organization (NAVBO) Online Mini-Symposia
DESCRIPTION:An online mini-symposium featuring four presentations:\n\nRenal stromal netrin-1 signaling drives kidney arterial development (Xiaowu Gu\, UT Southwestern)\nInhibition of Notch signaling in pericytes leads to AVM-like lesions (Taliha Nadeem\, University of Illinois\, Chicago)\nDach1 Promotes Coronary Artery Endothelial Cell Specification (Brian Raftrey\, Stanford University)\nPro-angiogenic properties of Purified Exosome Product (PEP) (Ao Shi\, Mayo Clinic) The session will be moderated by Kayla Bayless\, Texas A&M University
URL:https://scienceinseattle.com/event/north-american-vascular-biology-organization-navbo-online-mini-symposia-3/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/03/NAVBO.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T120000
DTEND;TZID=America/Vancouver:20200421T130000
DTSTAMP:20260403T192617
CREATED:20200316T214238Z
LAST-MODIFIED:20200316T214238Z
UID:8585-1587470400-1587474000@scienceinseattle.com
SUMMARY:Women in Bio National Webinar: Fundraising Boot Camp for Life Science Startups: Successful Partnering
DESCRIPTION:Booking a full schedule of meetings at any conference requires understanding the platform and how to execute a strategic plan\, utilizing all the tools and resources available to you. You already know how to identify investors you match with and have your story straight. Now you must book as many meetings as possible. As the second webinar in a three-part series\, this workshop will discuss how to introduce your company to an investor and how to request a meeting. You are also going to learn the follow-up processes that make the argument of why you are investable and why an investor should meet with you.\n \nSeries Description \n\nIn preparation for Partnering with Investors and the Women In Bio Sponsored Pitch Challenge at RESI San Diego\, Life Science Nation (LSN) and Women In Bio’s Entrepreneur Center will offer three webinars: Messaging and Branding\, Successful Partnering\, and a Fundraising Bootcamp. \n\nWho should attend? \nAnyone considering or actively developing therapeutic\, medical device\, diagnostic\, or digital health technologies and raising their seed\, series A\, or series B\, up to $50 million\, to complete any early stage of development leading to commercialization. \n\nWhat you will learn? \nOur proven methodology for matching early stage life science companies with investors based on fit (sector\, subsector\, indication\, and stage of development) and getting your story straight for navigating the fundraising ecosystem and generating more compelling connections with investors. \n\nAbout Life Science Nation \nLife Science Nation (LSN) is a global partnering ecosystem that allows early-stage companies with compelling technology assets to get plugged into the early-stage investor and channel partner’s radars with minimal cost and a big ROI. LSN is a global matching platform for early-stage buyers and sellers across the domains of Drugs\, Devices\, Diagnostics and Digital Health – the “4 Ds”. LSN curates two databases: a buy-side of global cross-border early-stage investors/partners and a sell-side of global cross-domain technology assets. LSN also offers a sourcing and ranking service for clients who need to source and rank technology assets for channel\, pipeline and portfolio development. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series\, a funding superstructure that runs five times a year during J.P. Morgan in San Francisco (January)\, alongside BIO Europe (March)\, alongside BIO U.S (June)\, Boston (September) and Asia (November). LSN also owns and operates the Focus on Cures Accelerator (FOC) that provides startups a Boston-based footprint and helps them develop and execute a global investor and channel partner strategy. Learn more at www.lifesciencenation.com \n  \nSpeaker Bio \n\nBryanna Allison\, Business Development Manager RESI Conference Series\n\nWalk-Ins Accepted? \nWalk-ins are not accepted – be sure to register early! \n\nPricing Information* \nMembers: Free \nNon-Members/Free Unlimited Guest Members*: $30 \n*To access the Member rate\, click here to purchase a WIB membership. \n*Our webinar will take place at GoToWebinar. National staff will handle the registration through GoToWebinar. You will receive your join link from GoToWebinar prior to the event.\n \n  \nEvent Capacity \n500 \n  \nRegistration Deadline \nApril 20\, 2020 \n\nEvent Date/Time \nApril 21\, 2020 \n12:00 p.m. – 1:00 p.m. EST* \n*- Please note this webinar’s time is listed in Eastern Standard Time. (The webinar begins promptly at 12:00 p.m.) \nWebinar recording will be mailed out to all registrants and will be available in our members’ only webinar library a few days after the event. WIB Members can enjoy viewing all WIB webinars in our Members’ Only Video Library here.  \n  \nVenue \nGoToWebinar–your join link will be e-mailed to you from GoToWebinar prior to the event
URL:https://scienceinseattle.com/event/women-in-bio-national-webinar-fundraising-boot-camp-for-life-science-startups-successful-partnering/
LOCATION:WA
ATTACH;FMTTYPE=image/png:https://scienceinseattle.com/wp-content/uploads/sites/4/2019/06/Women-in-Bio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T120000
DTEND;TZID=America/Vancouver:20200421T130000
DTSTAMP:20260403T192617
CREATED:20200316T214238Z
LAST-MODIFIED:20200316T214238Z
UID:25537-1587470400-1587474000@scienceinseattle.com
SUMMARY:Women in Bio National Webinar: Fundraising Boot Camp for Life Science Startups: Successful Partnering
DESCRIPTION:Booking a full schedule of meetings at any conference requires understanding the platform and how to execute a strategic plan\, utilizing all the tools and resources available to you. You already know how to identify investors you match with and have your story straight. Now you must book as many meetings as possible. As the second webinar in a three-part series\, this workshop will discuss how to introduce your company to an investor and how to request a meeting. You are also going to learn the follow-up processes that make the argument of why you are investable and why an investor should meet with you.\n \nSeries Description \n\nIn preparation for Partnering with Investors and the Women In Bio Sponsored Pitch Challenge at RESI San Diego\, Life Science Nation (LSN) and Women In Bio’s Entrepreneur Center will offer three webinars: Messaging and Branding\, Successful Partnering\, and a Fundraising Bootcamp. \n\nWho should attend? \nAnyone considering or actively developing therapeutic\, medical device\, diagnostic\, or digital health technologies and raising their seed\, series A\, or series B\, up to $50 million\, to complete any early stage of development leading to commercialization. \n\nWhat you will learn? \nOur proven methodology for matching early stage life science companies with investors based on fit (sector\, subsector\, indication\, and stage of development) and getting your story straight for navigating the fundraising ecosystem and generating more compelling connections with investors. \n\nAbout Life Science Nation \nLife Science Nation (LSN) is a global partnering ecosystem that allows early-stage companies with compelling technology assets to get plugged into the early-stage investor and channel partner’s radars with minimal cost and a big ROI. LSN is a global matching platform for early-stage buyers and sellers across the domains of Drugs\, Devices\, Diagnostics and Digital Health – the “4 Ds”. LSN curates two databases: a buy-side of global cross-border early-stage investors/partners and a sell-side of global cross-domain technology assets. LSN also offers a sourcing and ranking service for clients who need to source and rank technology assets for channel\, pipeline and portfolio development. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series\, a funding superstructure that runs five times a year during J.P. Morgan in San Francisco (January)\, alongside BIO Europe (March)\, alongside BIO U.S (June)\, Boston (September) and Asia (November). LSN also owns and operates the Focus on Cures Accelerator (FOC) that provides startups a Boston-based footprint and helps them develop and execute a global investor and channel partner strategy. Learn more at www.lifesciencenation.com \n  \nSpeaker Bio \n\nBryanna Allison\, Business Development Manager RESI Conference Series\n\nWalk-Ins Accepted? \nWalk-ins are not accepted – be sure to register early! \n\nPricing Information* \nMembers: Free \nNon-Members/Free Unlimited Guest Members*: $30 \n*To access the Member rate\, click here to purchase a WIB membership. \n*Our webinar will take place at GoToWebinar. National staff will handle the registration through GoToWebinar. You will receive your join link from GoToWebinar prior to the event.\n \n  \nEvent Capacity \n500 \n  \nRegistration Deadline \nApril 20\, 2020 \n\nEvent Date/Time \nApril 21\, 2020 \n12:00 p.m. – 1:00 p.m. EST* \n*- Please note this webinar’s time is listed in Eastern Standard Time. (The webinar begins promptly at 12:00 p.m.) \nWebinar recording will be mailed out to all registrants and will be available in our members’ only webinar library a few days after the event. WIB Members can enjoy viewing all WIB webinars in our Members’ Only Video Library here.  \n  \nVenue \nGoToWebinar–your join link will be e-mailed to you from GoToWebinar prior to the event
URL:https://scienceinseattle.com/event/women-in-bio-national-webinar-fundraising-boot-camp-for-life-science-startups-successful-partnering-2/
LOCATION:WA
ATTACH;FMTTYPE=image/png:https://scienceinseattle.com/wp-content/uploads/sites/4/2019/06/Women-in-Bio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T120000
DTEND;TZID=America/Vancouver:20200421T130000
DTSTAMP:20260403T192617
CREATED:20200316T214238Z
LAST-MODIFIED:20200316T214238Z
UID:26502-1587470400-1587474000@scienceinseattle.com
SUMMARY:Women in Bio National Webinar: Fundraising Boot Camp for Life Science Startups: Successful Partnering
DESCRIPTION:Booking a full schedule of meetings at any conference requires understanding the platform and how to execute a strategic plan\, utilizing all the tools and resources available to you. You already know how to identify investors you match with and have your story straight. Now you must book as many meetings as possible. As the second webinar in a three-part series\, this workshop will discuss how to introduce your company to an investor and how to request a meeting. You are also going to learn the follow-up processes that make the argument of why you are investable and why an investor should meet with you.\n \nSeries Description \n\nIn preparation for Partnering with Investors and the Women In Bio Sponsored Pitch Challenge at RESI San Diego\, Life Science Nation (LSN) and Women In Bio’s Entrepreneur Center will offer three webinars: Messaging and Branding\, Successful Partnering\, and a Fundraising Bootcamp. \n\nWho should attend? \nAnyone considering or actively developing therapeutic\, medical device\, diagnostic\, or digital health technologies and raising their seed\, series A\, or series B\, up to $50 million\, to complete any early stage of development leading to commercialization. \n\nWhat you will learn? \nOur proven methodology for matching early stage life science companies with investors based on fit (sector\, subsector\, indication\, and stage of development) and getting your story straight for navigating the fundraising ecosystem and generating more compelling connections with investors. \n\nAbout Life Science Nation \nLife Science Nation (LSN) is a global partnering ecosystem that allows early-stage companies with compelling technology assets to get plugged into the early-stage investor and channel partner’s radars with minimal cost and a big ROI. LSN is a global matching platform for early-stage buyers and sellers across the domains of Drugs\, Devices\, Diagnostics and Digital Health – the “4 Ds”. LSN curates two databases: a buy-side of global cross-border early-stage investors/partners and a sell-side of global cross-domain technology assets. LSN also offers a sourcing and ranking service for clients who need to source and rank technology assets for channel\, pipeline and portfolio development. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series\, a funding superstructure that runs five times a year during J.P. Morgan in San Francisco (January)\, alongside BIO Europe (March)\, alongside BIO U.S (June)\, Boston (September) and Asia (November). LSN also owns and operates the Focus on Cures Accelerator (FOC) that provides startups a Boston-based footprint and helps them develop and execute a global investor and channel partner strategy. Learn more at www.lifesciencenation.com \n  \nSpeaker Bio \n\nBryanna Allison\, Business Development Manager RESI Conference Series\n\nWalk-Ins Accepted? \nWalk-ins are not accepted – be sure to register early! \n\nPricing Information* \nMembers: Free \nNon-Members/Free Unlimited Guest Members*: $30 \n*To access the Member rate\, click here to purchase a WIB membership. \n*Our webinar will take place at GoToWebinar. National staff will handle the registration through GoToWebinar. You will receive your join link from GoToWebinar prior to the event.\n \n  \nEvent Capacity \n500 \n  \nRegistration Deadline \nApril 20\, 2020 \n\nEvent Date/Time \nApril 21\, 2020 \n12:00 p.m. – 1:00 p.m. EST* \n*- Please note this webinar’s time is listed in Eastern Standard Time. (The webinar begins promptly at 12:00 p.m.) \nWebinar recording will be mailed out to all registrants and will be available in our members’ only webinar library a few days after the event. WIB Members can enjoy viewing all WIB webinars in our Members’ Only Video Library here.  \n  \nVenue \nGoToWebinar–your join link will be e-mailed to you from GoToWebinar prior to the event
URL:https://scienceinseattle.com/event/women-in-bio-national-webinar-fundraising-boot-camp-for-life-science-startups-successful-partnering-3/
LOCATION:WA
ATTACH;FMTTYPE=image/png:https://scienceinseattle.com/wp-content/uploads/sites/4/2019/06/Women-in-Bio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T120000
DTEND;TZID=America/Vancouver:20200421T130000
DTSTAMP:20260403T192617
CREATED:20200409T201409Z
LAST-MODIFIED:20200409T201409Z
UID:8836-1587470400-1587474000@scienceinseattle.com
SUMMARY:Webinar: From ACE2 to COVID19
DESCRIPTION:
URL:https://scienceinseattle.com/event/webinar-from-ace2-to-covid19/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/04/Seminar_Flyer_Penninger-pdf.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T120000
DTEND;TZID=America/Vancouver:20200421T130000
DTSTAMP:20260403T192617
CREATED:20200409T201409Z
LAST-MODIFIED:20200409T201409Z
UID:25557-1587470400-1587474000@scienceinseattle.com
SUMMARY:Webinar: From ACE2 to COVID19
DESCRIPTION:
URL:https://scienceinseattle.com/event/webinar-from-ace2-to-covid19-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/04/Seminar_Flyer_Penninger-pdf.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200421T120000
DTEND;TZID=America/Vancouver:20200421T130000
DTSTAMP:20260403T192617
CREATED:20200409T201409Z
LAST-MODIFIED:20200409T201409Z
UID:26522-1587470400-1587474000@scienceinseattle.com
SUMMARY:Webinar: From ACE2 to COVID19
DESCRIPTION:
URL:https://scienceinseattle.com/event/webinar-from-ace2-to-covid19-3/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/04/Seminar_Flyer_Penninger-pdf.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T080000
DTEND;TZID=America/Vancouver:20200425T170000
DTSTAMP:20260403T192617
CREATED:20200413T220621Z
LAST-MODIFIED:20200413T220621Z
UID:8892-1587542400-1587834000@scienceinseattle.com
SUMMARY:The Allied Genetics Conference (TAGC) Online
DESCRIPTION:TAGC is a unique conference organized by the Genetics Society of America that fosters collaboration by alternating community-specific sessions with cross-community thematic sessions. After the in-person version of the meeting was canceled\, we recreated TAGC Online as a virtual meeting that allows you to share your research and stay connected without leaving your home. \nJoin us online April 22–25\, 2020. There is no cost to attend\, but you must register in advance! \nAt TAGC Online you can join colleagues from the C. elegans\,  Drosophila\, mammalian\, Xenopus\, yeast\, zebrafish\, and population\, evolutionary\, and quantitative genetics (PEQG) research communities—along with other researchers studying humans\, plants\, and agricultural species. In addition to the Community Sessions\, Thematic Sessions bring the communities together around unifying themes. \nOn April 22–25\, both Community and Thematic Sessions will be presented live online. TAGC 2020 Online will also include posters and inspiring Keynote Speakers\, followed by a program of poster discussion sessions and two-hour workshops in the weeks after the main event. TAGC 2020 is organized by dedicated members of the GSA community. We hope you’ll join us for this exciting experiment!
URL:https://scienceinseattle.com/event/the-allied-genetics-conference-tagc-online/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T080000
DTEND;TZID=America/Vancouver:20200425T170000
DTSTAMP:20260403T192617
CREATED:20200413T220621Z
LAST-MODIFIED:20200413T220621Z
UID:25559-1587542400-1587834000@scienceinseattle.com
SUMMARY:The Allied Genetics Conference (TAGC) Online
DESCRIPTION:TAGC is a unique conference organized by the Genetics Society of America that fosters collaboration by alternating community-specific sessions with cross-community thematic sessions. After the in-person version of the meeting was canceled\, we recreated TAGC Online as a virtual meeting that allows you to share your research and stay connected without leaving your home. \nJoin us online April 22–25\, 2020. There is no cost to attend\, but you must register in advance! \nAt TAGC Online you can join colleagues from the C. elegans\,  Drosophila\, mammalian\, Xenopus\, yeast\, zebrafish\, and population\, evolutionary\, and quantitative genetics (PEQG) research communities—along with other researchers studying humans\, plants\, and agricultural species. In addition to the Community Sessions\, Thematic Sessions bring the communities together around unifying themes. \nOn April 22–25\, both Community and Thematic Sessions will be presented live online. TAGC 2020 Online will also include posters and inspiring Keynote Speakers\, followed by a program of poster discussion sessions and two-hour workshops in the weeks after the main event. TAGC 2020 is organized by dedicated members of the GSA community. We hope you’ll join us for this exciting experiment!
URL:https://scienceinseattle.com/event/the-allied-genetics-conference-tagc-online-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T080000
DTEND;TZID=America/Vancouver:20200425T170000
DTSTAMP:20260403T192617
CREATED:20200413T220621Z
LAST-MODIFIED:20200413T220621Z
UID:26524-1587542400-1587834000@scienceinseattle.com
SUMMARY:The Allied Genetics Conference (TAGC) Online
DESCRIPTION:TAGC is a unique conference organized by the Genetics Society of America that fosters collaboration by alternating community-specific sessions with cross-community thematic sessions. After the in-person version of the meeting was canceled\, we recreated TAGC Online as a virtual meeting that allows you to share your research and stay connected without leaving your home. \nJoin us online April 22–25\, 2020. There is no cost to attend\, but you must register in advance! \nAt TAGC Online you can join colleagues from the C. elegans\,  Drosophila\, mammalian\, Xenopus\, yeast\, zebrafish\, and population\, evolutionary\, and quantitative genetics (PEQG) research communities—along with other researchers studying humans\, plants\, and agricultural species. In addition to the Community Sessions\, Thematic Sessions bring the communities together around unifying themes. \nOn April 22–25\, both Community and Thematic Sessions will be presented live online. TAGC 2020 Online will also include posters and inspiring Keynote Speakers\, followed by a program of poster discussion sessions and two-hour workshops in the weeks after the main event. TAGC 2020 is organized by dedicated members of the GSA community. We hope you’ll join us for this exciting experiment!
URL:https://scienceinseattle.com/event/the-allied-genetics-conference-tagc-online-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T090000
DTEND;TZID=America/Vancouver:20200422T110000
DTSTAMP:20260403T192617
CREATED:20200330T191012Z
LAST-MODIFIED:20200330T191112Z
UID:8701-1587546000-1587553200@scienceinseattle.com
SUMMARY:Webinar: Every Cell Has Its Place - In Situ Sequencing of Tissue Samples at Single-Cell Resolution
DESCRIPTION:Single-cell RNA sequencing (scRNA-seq) has revolutionized the understanding of tissue complexity by dissecting transcriptomic heterogeneity and revealing previously unknown cell types and states. However\, scRNA-seq does not allow the visualization of spatial organization of single cells within the tissue. In order to overcome this limitation\, spatial gene expression profiling technologies have emerged that aim to localize molecularly defined cell types within the morphological context. In situ sequencing (ISS) can rapidly analyze and visualize the expression of hundreds of genes within morphologically intact tissue samples at single-cell resolution. ISS helps researchers to understand complex biological and pathological mechanisms and to localize and validate new drug targets. \nIn this webinar\, we will outline the benefits of ISS and showcase how it can complement spatial transcriptomics technology in the task of unraveling the role of amyloid-ß plaques in the neurogenerative process of Alzheimer’s disease. \nDuring this webinar\, the speakers will: \n\nIntroduce ISS technology and how it enables simultaneous spatial analysis of hundreds of genes in tissue samples at single-cell resolution\nShow how ISS has helped shed light on the role of amyloid-ß plaques in Alzheimer’s disease\nDiscuss applications and performance of ISS in other research areas\nAnswer your questions during the live broadcast.\n\nThis webinar will last for approximately 60 minutes.
URL:https://scienceinseattle.com/event/webinar-every-cell-has-its-place-in-situ-sequencing-of-tissue-samples-at-single-cell-resolution/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/03/Every-cell-has-its-place-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T090000
DTEND;TZID=America/Vancouver:20200422T110000
DTSTAMP:20260403T192617
CREATED:20200330T191012Z
LAST-MODIFIED:20200330T191012Z
UID:25546-1587546000-1587553200@scienceinseattle.com
SUMMARY:Webinar: Every Cell Has Its Place - In Situ Sequencing of Tissue Samples at Single-Cell Resolution
DESCRIPTION:Single-cell RNA sequencing (scRNA-seq) has revolutionized the understanding of tissue complexity by dissecting transcriptomic heterogeneity and revealing previously unknown cell types and states. However\, scRNA-seq does not allow the visualization of spatial organization of single cells within the tissue. In order to overcome this limitation\, spatial gene expression profiling technologies have emerged that aim to localize molecularly defined cell types within the morphological context. In situ sequencing (ISS) can rapidly analyze and visualize the expression of hundreds of genes within morphologically intact tissue samples at single-cell resolution. ISS helps researchers to understand complex biological and pathological mechanisms and to localize and validate new drug targets. \nIn this webinar\, we will outline the benefits of ISS and showcase how it can complement spatial transcriptomics technology in the task of unraveling the role of amyloid-ß plaques in the neurogenerative process of Alzheimer’s disease. \nDuring this webinar\, the speakers will: \n\nIntroduce ISS technology and how it enables simultaneous spatial analysis of hundreds of genes in tissue samples at single-cell resolution\nShow how ISS has helped shed light on the role of amyloid-ß plaques in Alzheimer’s disease\nDiscuss applications and performance of ISS in other research areas\nAnswer your questions during the live broadcast.\n\nThis webinar will last for approximately 60 minutes.
URL:https://scienceinseattle.com/event/webinar-every-cell-has-its-place-in-situ-sequencing-of-tissue-samples-at-single-cell-resolution-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/03/Every-cell-has-its-place-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T090000
DTEND;TZID=America/Vancouver:20200422T110000
DTSTAMP:20260403T192617
CREATED:20200330T191012Z
LAST-MODIFIED:20200330T191012Z
UID:26511-1587546000-1587553200@scienceinseattle.com
SUMMARY:Webinar: Every Cell Has Its Place - In Situ Sequencing of Tissue Samples at Single-Cell Resolution
DESCRIPTION:Single-cell RNA sequencing (scRNA-seq) has revolutionized the understanding of tissue complexity by dissecting transcriptomic heterogeneity and revealing previously unknown cell types and states. However\, scRNA-seq does not allow the visualization of spatial organization of single cells within the tissue. In order to overcome this limitation\, spatial gene expression profiling technologies have emerged that aim to localize molecularly defined cell types within the morphological context. In situ sequencing (ISS) can rapidly analyze and visualize the expression of hundreds of genes within morphologically intact tissue samples at single-cell resolution. ISS helps researchers to understand complex biological and pathological mechanisms and to localize and validate new drug targets. \nIn this webinar\, we will outline the benefits of ISS and showcase how it can complement spatial transcriptomics technology in the task of unraveling the role of amyloid-ß plaques in the neurogenerative process of Alzheimer’s disease. \nDuring this webinar\, the speakers will: \n\nIntroduce ISS technology and how it enables simultaneous spatial analysis of hundreds of genes in tissue samples at single-cell resolution\nShow how ISS has helped shed light on the role of amyloid-ß plaques in Alzheimer’s disease\nDiscuss applications and performance of ISS in other research areas\nAnswer your questions during the live broadcast.\n\nThis webinar will last for approximately 60 minutes.
URL:https://scienceinseattle.com/event/webinar-every-cell-has-its-place-in-situ-sequencing-of-tissue-samples-at-single-cell-resolution-3/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/03/Every-cell-has-its-place-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T100000
DTEND;TZID=America/Vancouver:20200422T113000
DTSTAMP:20260403T192617
CREATED:20200416T220153Z
LAST-MODIFIED:20200416T220153Z
UID:8929-1587549600-1587555000@scienceinseattle.com
SUMMARY:STAT Digital Event Series: Combating Covid-19
DESCRIPTION:The pandemic caused by the novel coronavirus has shut down countries around the world. One of society’s biggest hopes is that treatments or even vaccines can be developed. \nJoin STAT for a three-part digital event series covering the race for new medicines that will impact Covid-19. The audience will be joined by executives from companies leading the way in developing treatments\, who will come prepared to answer tough questions. They’ll discuss current findings\, clinical trials\, and efforts to expedite approvals as we face this global pandemic. \nThis series will take place on Zoom\, an interactive platform where attendees will be able to not only see the discussions live\, but also participate by asking questions during the event. Access to the event is free. Access to the Zoom platform is limited to the first 1\,000 attendees; any additional attendees will be able to watch the conversation in real-time via a live stream on STAT’s website. \nSchedule: Please note\, dates and times are subject to change as the story evolves. \nPart 1: Antibody drugs that target the coronavirus. April 8\, 2020 at 1 PM EST \n\nSponsor Introduction: Stephen J. Ubl\, president and chief executive officer\, PhRMA\nGeorge Yancopoulos\, co-founder\, president and chief scientific officer\, Regeneron\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT\n\nYou can watch the recorded conversation with George Yancopoulos here. \nPart 2: Antiviral treatments — what are the odds? April 22\, 2020 at 1PM EST \n\nSponsor Introduction: Richard Moscicki\, M.D.\, chief medical officer and executive vice president of Science and Regulatory Advocacy\, PhRMA\nDiana Brainard\, senior vice president\, HIV and Emerging Viral Infections at Gilead Sciences\, Inc.\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT\n\nPart 3: Vaccines — can they come soon enough? May 6\, 2020 at 1PM EST \n\nSponsor Introduction: Clem Lewin\, Ph.D.\, associate vice president of R&D strategy for vaccines\, Sanofi\nTal Zaks\, chief medical officer\, Moderna\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT
URL:https://scienceinseattle.com/event/stat-digital-event-series-combating-covid-19/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/04/STAT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T100000
DTEND;TZID=America/Vancouver:20200422T113000
DTSTAMP:20260403T192617
CREATED:20200416T220153Z
LAST-MODIFIED:20200416T220153Z
UID:25562-1587549600-1587555000@scienceinseattle.com
SUMMARY:STAT Digital Event Series: Combating Covid-19
DESCRIPTION:The pandemic caused by the novel coronavirus has shut down countries around the world. One of society’s biggest hopes is that treatments or even vaccines can be developed. \nJoin STAT for a three-part digital event series covering the race for new medicines that will impact Covid-19. The audience will be joined by executives from companies leading the way in developing treatments\, who will come prepared to answer tough questions. They’ll discuss current findings\, clinical trials\, and efforts to expedite approvals as we face this global pandemic. \nThis series will take place on Zoom\, an interactive platform where attendees will be able to not only see the discussions live\, but also participate by asking questions during the event. Access to the event is free. Access to the Zoom platform is limited to the first 1\,000 attendees; any additional attendees will be able to watch the conversation in real-time via a live stream on STAT’s website. \nSchedule: Please note\, dates and times are subject to change as the story evolves. \nPart 1: Antibody drugs that target the coronavirus. April 8\, 2020 at 1 PM EST \n\nSponsor Introduction: Stephen J. Ubl\, president and chief executive officer\, PhRMA\nGeorge Yancopoulos\, co-founder\, president and chief scientific officer\, Regeneron\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT\n\nYou can watch the recorded conversation with George Yancopoulos here. \nPart 2: Antiviral treatments — what are the odds? April 22\, 2020 at 1PM EST \n\nSponsor Introduction: Richard Moscicki\, M.D.\, chief medical officer and executive vice president of Science and Regulatory Advocacy\, PhRMA\nDiana Brainard\, senior vice president\, HIV and Emerging Viral Infections at Gilead Sciences\, Inc.\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT\n\nPart 3: Vaccines — can they come soon enough? May 6\, 2020 at 1PM EST \n\nSponsor Introduction: Clem Lewin\, Ph.D.\, associate vice president of R&D strategy for vaccines\, Sanofi\nTal Zaks\, chief medical officer\, Moderna\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT
URL:https://scienceinseattle.com/event/stat-digital-event-series-combating-covid-19-2/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/04/STAT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T100000
DTEND;TZID=America/Vancouver:20200422T113000
DTSTAMP:20260403T192617
CREATED:20200416T220153Z
LAST-MODIFIED:20200416T220153Z
UID:26527-1587549600-1587555000@scienceinseattle.com
SUMMARY:STAT Digital Event Series: Combating Covid-19
DESCRIPTION:The pandemic caused by the novel coronavirus has shut down countries around the world. One of society’s biggest hopes is that treatments or even vaccines can be developed. \nJoin STAT for a three-part digital event series covering the race for new medicines that will impact Covid-19. The audience will be joined by executives from companies leading the way in developing treatments\, who will come prepared to answer tough questions. They’ll discuss current findings\, clinical trials\, and efforts to expedite approvals as we face this global pandemic. \nThis series will take place on Zoom\, an interactive platform where attendees will be able to not only see the discussions live\, but also participate by asking questions during the event. Access to the event is free. Access to the Zoom platform is limited to the first 1\,000 attendees; any additional attendees will be able to watch the conversation in real-time via a live stream on STAT’s website. \nSchedule: Please note\, dates and times are subject to change as the story evolves. \nPart 1: Antibody drugs that target the coronavirus. April 8\, 2020 at 1 PM EST \n\nSponsor Introduction: Stephen J. Ubl\, president and chief executive officer\, PhRMA\nGeorge Yancopoulos\, co-founder\, president and chief scientific officer\, Regeneron\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT\n\nYou can watch the recorded conversation with George Yancopoulos here. \nPart 2: Antiviral treatments — what are the odds? April 22\, 2020 at 1PM EST \n\nSponsor Introduction: Richard Moscicki\, M.D.\, chief medical officer and executive vice president of Science and Regulatory Advocacy\, PhRMA\nDiana Brainard\, senior vice president\, HIV and Emerging Viral Infections at Gilead Sciences\, Inc.\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT\n\nPart 3: Vaccines — can they come soon enough? May 6\, 2020 at 1PM EST \n\nSponsor Introduction: Clem Lewin\, Ph.D.\, associate vice president of R&D strategy for vaccines\, Sanofi\nTal Zaks\, chief medical officer\, Moderna\nMatt Herper\, senior writer\, medicine\, and editorial director of events\, STAT
URL:https://scienceinseattle.com/event/stat-digital-event-series-combating-covid-19-3/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/04/STAT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T160000
DTEND;TZID=America/Vancouver:20200422T170000
DTSTAMP:20260403T192617
CREATED:20200414T225636Z
LAST-MODIFIED:20200414T225636Z
UID:8905-1587571200-1587574800@scienceinseattle.com
SUMMARY:Science Matters: Curiosity Drives Discovery
DESCRIPTION:COVID-19 has propelled scientists into the limelight as the world awaits the availability of new tests\, drugs\, and vaccines to help fight the pandemic. \nWho are these men and women of science? What drives them to pursue their work? How do today’s scientific discoveries shape tomorrow’s breakthroughs. \nJoin us for a conversation with PNRI scientist David Galas\, PhD. Some of his notable achievements include overseeing the Human Genome Project\, discovering a technology that was recently used by Abbott Laboratories to develop a rapid test for COVID-19\, and developing a groundbreaking mathematical approach to unraveling the complexities of biology. \nDr. Galas will share stories about his life and career as a scientist\, and his thoughts on the role of science and technology in today’s world.
URL:https://scienceinseattle.com/event/science-matters-curiosity-drives-discovery-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/04/PNRI.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T160000
DTEND;TZID=America/Vancouver:20200422T170000
DTSTAMP:20260403T192617
CREATED:20200414T225636Z
LAST-MODIFIED:20200414T225636Z
UID:25560-1587571200-1587574800@scienceinseattle.com
SUMMARY:Science Matters: Curiosity Drives Discovery
DESCRIPTION:COVID-19 has propelled scientists into the limelight as the world awaits the availability of new tests\, drugs\, and vaccines to help fight the pandemic. \nWho are these men and women of science? What drives them to pursue their work? How do today’s scientific discoveries shape tomorrow’s breakthroughs. \nJoin us for a conversation with PNRI scientist David Galas\, PhD. Some of his notable achievements include overseeing the Human Genome Project\, discovering a technology that was recently used by Abbott Laboratories to develop a rapid test for COVID-19\, and developing a groundbreaking mathematical approach to unraveling the complexities of biology. \nDr. Galas will share stories about his life and career as a scientist\, and his thoughts on the role of science and technology in today’s world.
URL:https://scienceinseattle.com/event/science-matters-curiosity-drives-discovery-2-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/04/PNRI.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200422T160000
DTEND;TZID=America/Vancouver:20200422T170000
DTSTAMP:20260403T192617
CREATED:20200414T225636Z
LAST-MODIFIED:20200414T225636Z
UID:26525-1587571200-1587574800@scienceinseattle.com
SUMMARY:Science Matters: Curiosity Drives Discovery
DESCRIPTION:COVID-19 has propelled scientists into the limelight as the world awaits the availability of new tests\, drugs\, and vaccines to help fight the pandemic. \nWho are these men and women of science? What drives them to pursue their work? How do today’s scientific discoveries shape tomorrow’s breakthroughs. \nJoin us for a conversation with PNRI scientist David Galas\, PhD. Some of his notable achievements include overseeing the Human Genome Project\, discovering a technology that was recently used by Abbott Laboratories to develop a rapid test for COVID-19\, and developing a groundbreaking mathematical approach to unraveling the complexities of biology. \nDr. Galas will share stories about his life and career as a scientist\, and his thoughts on the role of science and technology in today’s world.
URL:https://scienceinseattle.com/event/science-matters-curiosity-drives-discovery-2-3/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/04/PNRI.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200423T150000
DTEND;TZID=America/Vancouver:20200423T160000
DTSTAMP:20260403T192617
CREATED:20200413T175655Z
LAST-MODIFIED:20200413T175655Z
UID:8844-1587654000-1587657600@scienceinseattle.com
SUMMARY:Responding to COVID-19:  A Ground-Zero Perspective from Washington’s Life Science Community
DESCRIPTION:Life Science Washington and the University of Washington have teamed up to share stories and perspectives from scientists\, researchers\, and policymakers about the COVID-19 response. \n  \nThis webinar\, moderated by Luke Timmerman\, will explore how Washington institutions are partnering with public health officials to lower our regional pandemic curve. The Seattle region was the epicenter of the COVID-19 virus and therefore first to address the crisis both through our life science research institutions and public policy. \nLuke Timmerman is an award-winning journalist who has been covering biotechnology since 2001. Before founding Timmerman Report in 2015\, Luke wrote about the industry for a regional newspaper (The Seattle Times)\, a global financial publication (Bloomberg News)\, and an online startup (Xconomy). Luke’s first book\, “Hood: Trailblazer of the Genomics Age” was called a “must-read” by Forbes\, and named one of the “100 Best Indie Books of 2017” by Kirkus Reviews. \nLuke was named one of the 100 Most Influential People in Biotechnology by Scientific American in 2015. He has won a number of journalism prizes\, including the Scripps Howard National Journalism Award\, the Association of Health Care Journalists Award\, and the Society of American Business Editors and Writers (SABEW) award. Luke received his bachelor’s degree in journalism from the University of Wisconsin-Madison in 1997. For the 2005-2006 academic year\, he was awarded a Knight Science Journalism Fellow at MIT.
URL:https://scienceinseattle.com/event/responding-to-covid-19-a-ground-zero-perspective-from-washingtons-life-science-community/
LOCATION:Online
ORGANIZER;CN="Life Science Washington":MAILTO:kaitlyn@lifesciencewa.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200423T150000
DTEND;TZID=America/Vancouver:20200423T160000
DTSTAMP:20260403T192617
CREATED:20200413T175655Z
LAST-MODIFIED:20200413T175655Z
UID:25558-1587654000-1587657600@scienceinseattle.com
SUMMARY:Responding to COVID-19:  A Ground-Zero Perspective from Washington’s Life Science Community
DESCRIPTION:Life Science Washington and the University of Washington have teamed up to share stories and perspectives from scientists\, researchers\, and policymakers about the COVID-19 response. \n  \nThis webinar\, moderated by Luke Timmerman\, will explore how Washington institutions are partnering with public health officials to lower our regional pandemic curve. The Seattle region was the epicenter of the COVID-19 virus and therefore first to address the crisis both through our life science research institutions and public policy. \nLuke Timmerman is an award-winning journalist who has been covering biotechnology since 2001. Before founding Timmerman Report in 2015\, Luke wrote about the industry for a regional newspaper (The Seattle Times)\, a global financial publication (Bloomberg News)\, and an online startup (Xconomy). Luke’s first book\, “Hood: Trailblazer of the Genomics Age” was called a “must-read” by Forbes\, and named one of the “100 Best Indie Books of 2017” by Kirkus Reviews. \nLuke was named one of the 100 Most Influential People in Biotechnology by Scientific American in 2015. He has won a number of journalism prizes\, including the Scripps Howard National Journalism Award\, the Association of Health Care Journalists Award\, and the Society of American Business Editors and Writers (SABEW) award. Luke received his bachelor’s degree in journalism from the University of Wisconsin-Madison in 1997. For the 2005-2006 academic year\, he was awarded a Knight Science Journalism Fellow at MIT.
URL:https://scienceinseattle.com/event/responding-to-covid-19-a-ground-zero-perspective-from-washingtons-life-science-community-2/
LOCATION:Online
ORGANIZER;CN="Life Science Washington":MAILTO:kaitlyn@lifesciencewa.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200423T150000
DTEND;TZID=America/Vancouver:20200423T160000
DTSTAMP:20260403T192617
CREATED:20200413T175655Z
LAST-MODIFIED:20200413T175655Z
UID:26523-1587654000-1587657600@scienceinseattle.com
SUMMARY:Responding to COVID-19:  A Ground-Zero Perspective from Washington’s Life Science Community
DESCRIPTION:Life Science Washington and the University of Washington have teamed up to share stories and perspectives from scientists\, researchers\, and policymakers about the COVID-19 response. \n  \nThis webinar\, moderated by Luke Timmerman\, will explore how Washington institutions are partnering with public health officials to lower our regional pandemic curve. The Seattle region was the epicenter of the COVID-19 virus and therefore first to address the crisis both through our life science research institutions and public policy. \nLuke Timmerman is an award-winning journalist who has been covering biotechnology since 2001. Before founding Timmerman Report in 2015\, Luke wrote about the industry for a regional newspaper (The Seattle Times)\, a global financial publication (Bloomberg News)\, and an online startup (Xconomy). Luke’s first book\, “Hood: Trailblazer of the Genomics Age” was called a “must-read” by Forbes\, and named one of the “100 Best Indie Books of 2017” by Kirkus Reviews. \nLuke was named one of the 100 Most Influential People in Biotechnology by Scientific American in 2015. He has won a number of journalism prizes\, including the Scripps Howard National Journalism Award\, the Association of Health Care Journalists Award\, and the Society of American Business Editors and Writers (SABEW) award. Luke received his bachelor’s degree in journalism from the University of Wisconsin-Madison in 1997. For the 2005-2006 academic year\, he was awarded a Knight Science Journalism Fellow at MIT.
URL:https://scienceinseattle.com/event/responding-to-covid-19-a-ground-zero-perspective-from-washingtons-life-science-community-3/
LOCATION:Online
ORGANIZER;CN="Life Science Washington":MAILTO:kaitlyn@lifesciencewa.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20200427T080000
DTEND;TZID=America/Vancouver:20200427T090000
DTSTAMP:20260403T192617
CREATED:20200423T225335Z
LAST-MODIFIED:20200423T225335Z
UID:8996-1587974400-1587978000@scienceinseattle.com
SUMMARY:STAT Video Chat: A Conversation on the Coronavirus with Rich Besser
DESCRIPTION:A STAT Video chat with former acting director of the CDC and current CEO of the Robert Wood Johnson Foundation\, Rich Besser\n\n\n\n\n\n\nAbout this Event\n\n\nABOUT THE CHAT \nRich Besser is a leading public health expert and the former acting director of the Centers for Disease Control and Prevention. He has drawn on his experience to offer both criticism and commendation of global response efforts to the pandemic\, and has emphasized the health inequities being brought to light as a result. Join STAT’s senior infectious diseases and global health reporter\, Helen Branswell\, for a live video chat with Dr. Besser\, who is now president and CEO of the Robert Wood Johnson Foundation\, at 11 a.m. EDT on Monday\, April 27. They’ll be talking about the current state of the pandemic\, how communities across the country are being impacted\, and how we can work together in response. \nQuestions for Dr. Besser? Submit a question in advance when you register. \nHOW IT WORKS \nWe’ll be hosting this live chat as a Zoom webinar. Register here to sign up for the chat\, and we’ll reach out to you at the email address provided with a link to access the chat. A live stream link will also be provided. Please feel free to join there if the Zoom room is full.
URL:https://scienceinseattle.com/event/stat-video-chat-a-conversation-on-the-coronavirus-with-rich-besser/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinseattle.com/wp-content/uploads/sites/4/2020/04/STAT.jpg
END:VEVENT
END:VCALENDAR